UPC
Universe Pharmaceuticals Inc.NASDAQHealthcare$3.16-7.28%ClosedMarket Cap: $1.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.03
P/S
0.09
EV/EBITDA
7.76
DCF Value
$6,872.26
FCF Yield
-322.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
35.3%
Operating Margin
-16.3%
Net Margin
-20.6%
ROE
-6.6%
ROA
-5.3%
ROIC
-4.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $8.7M | 36.0% | $-589.2K | $-387.3K | $-0.69 | — |
| FY 2025 | $17.9M | 35.3% | $-2.9M | $-3.7M | $-1,055.75 | — |
| Q2 2025 | $9.2M | 34.6% | $-2.3M | $-3.3M | $-944.40 | — |
| Q4 2024 | $10.1M | 27.9% | $-6.3M | $4.4M | $719.79 | — |
| FY 2024 | $23.0M | 26.4% | $-8.0M | $-8.7M | $-1,436.12 | — |
| Q2 2024 | $12.9M | 25.2% | $-1.7M | $-13.1M | $-2,155.91 | — |
| Q4 2023 | $13.8M | 29.4% | $-3.7M | $-5.4M | $-919.74 | — |
| FY 2023 | $32.3M | 31.9% | $-3.5M | $-6.2M | $-1,040.53 | — |
| Q2 2023 | $18.5M | 32.6% | $149.3K | $-715.4K | $-120.79 | — |
| Q4 2022 | $15.9M | 50.5% | $-10.1M | $-10.5M | $-1,767.40 | — |
| FY 2022 | $40.1M | 54.5% | $-7.0M | $-8.7M | $-1,475.02 | — |
| Q2 2022 | $24.2M | 56.3% | $2.7M | $1.7M | $292.37 | — |